Floatz logo

mb07133

Tolerance

Xi'an Xintong Pharmaceutical Research Co.,Ltd.Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Tolerance cohort.

Asset / SponsorPhaseRating
Vaxigrip
Medical University of Warsaw
Phase 4BB
Ertugliflozin
Getz Pharma
Phase 4BB
Acetylsalicylic Acid
Northern California Institute of Research and Education
Phase 2B
Hydrochlorothiazide
Northern California Institute of Research and Education
Phase 2B
SIMVASTATIN
Northern California Institute of Research and Education
Phase 2B

View all 10 →

Same molecule, other indications

mb07133 is also rated in:

Safety IssuesDormant
B
Indicative ·
60 / 100
View asset →
MTDDormant
CCC
Indicative ·
48 / 100
View asset →
EfficacyDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →